Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner, Ph.D., to President and Founder
“The Board is pleased to have recruited an individual with an ideal
industry background, as well as public company experience, to assume
leadership of Aerpio. Dr. Hoffman is well-positioned to lead Aerpio
successfully into the future,” said
Dr. Hoffman joins
“I’m very excited to join Aerpio and work with the existing management team to develop and commercialize products affecting the Tie2 pathway,” said Dr. Hoffman. “We believe the Tie2 pathway represents an important target not only in ophthalmology, but in the pathogenesis of 'leaky vasculature' and which produces significant morbidity in patients with diabetes and other medical conditions. By activating Tie2 we believe we could possibly have a major impact in diabetes care, beginning by slowing the progression of diabetic retinopathy to diabetic macular edema and ultimately, blindness.”
“Dr. Hoffman’s entrepreneurial background, business savvy, industry experience and strong relationships within the investment community make him an excellent choice to lead Aerpio going forward,” stated Dr. Gardner. “Dr. Hoffman adds management depth, as well as technical strength, which will be critical as we progress our drug candidates.”
About
Forward Looking Statements
This press release contains forward-looking statements. Statements in
this press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other things,
the future plans and directions for the Company, the appointment of Dr.
Hoffman as the Company’s Chief Executive Officer and the expected
appointment as a member of its board of directors, the continued role of
Dr. Gardner as President and Founder of the Company, and the development
of the Company’s product candidates. Actual results could differ from
those projected in any forward-looking statements due to several risk
factors. Such factors include, among others, the ability to raise the
additional funding needed to continue to develop AKB-9778 or other
product development plans, the inherent uncertainties associated with
the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171010005875/en/
Source:
Investor & Media:
Aerpio
Pharmaceuticals, Inc.
Dhaval Desai
Vice President of
Medical Affairs
ddesai@aerpio.com
or
Burns
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Media:
Justin
Jackson
jjackson@burnsmc.com
or
Investors:
Ami
Bavishi
abavishi@burnsmc.com